Wedbush Reaffirms Outperform Rating for Chimerix (NASDAQ:CMRX)

Wedbush restated their outperform rating on shares of Chimerix (NASDAQ:CMRX - Free Report) in a research note published on Tuesday,RTT News reports. They currently have a $7.00 price objective on the biopharmaceutical company's stock, up from their previous price objective of $6.00. Wedbush also issued estimates for Chimerix's Q4 2025 earnings at $0.74 EPS, FY2025 earnings at ($0.03) EPS, FY2026 earnings at ($0.89) EPS, FY2027 earnings at $0.02 EPS and FY2028 earnings at $0.58 EPS.

Separately, HC Wainwright reissued a "buy" rating and set a $11.00 price objective on shares of Chimerix in a research note on Tuesday.

Chimerix Price Performance

NASDAQ:CMRX traded down $0.01 during mid-day trading on Tuesday, hitting $5.16. 1,966,579 shares of the company's stock were exchanged, compared to its average volume of 1,665,416. Chimerix has a one year low of $0.75 and a one year high of $5.53. The business has a fifty day moving average price of $3.77 and a 200 day moving average price of $1.95. The company has a market cap of $464.45 million, a PE ratio of -5.49 and a beta of 0.35.

Insiders Place Their Bets

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares of the company's stock, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders sold 20,760 shares of company stock valued at $91,175. Insiders own 13.10% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Assenagon Asset Management S.A. raised its holdings in Chimerix by 154.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company's stock worth $2,846,000 after buying an additional 496,823 shares during the last quarter. Palumbo Wealth Management LLC purchased a new position in shares of Chimerix during the fourth quarter valued at approximately $221,000. Peapod Lane Capital LLC purchased a new position in shares of Chimerix during the fourth quarter valued at approximately $2,626,000. Valeo Financial Advisors LLC raised its holdings in shares of Chimerix by 78.8% during the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company's stock valued at $509,000 after purchasing an additional 64,420 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock valued at $321,000 after purchasing an additional 138,098 shares during the last quarter. 45.42% of the stock is owned by hedge funds and other institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.